Literature DB >> 9825947

Does thalidomide cause second generation birth defects?

D Smithells1.   

Abstract

The proposed association between thalidomide and second generation birth defects is an improbable hypotheses which lacks, so far, any credible scientific foundation. However, the media have chosen to give it extensive coverage. So much so that even the hard-headed scientist may start wondering if there is anything in it. However, there is no reason to suppose that people with birth defects caused by exposure to thalidomide during embryonic life have any greater or lesser chance of producing children with birth defects. This appears to be the case in practice. The question could be reworded to, 'Can thalidomide be responsible for identical, or similar, birth defects in 2 generations of the same family?' For such a phenomenon to be possible, a mechanism must be proposed and there appear to be only 2 possible candidates. The first is that the defects in the parent, originating during embryonic life, have somehow been transmitted to the next generation. The second is that thalidomide is a mutagen as well as a teratogen. The first mechanism can be excluded, since Lamarckism has long since been abandoned by scientists. The hypothesis that thalidomide is a mutagen and might be responsible for birth defects in the children of thalidomide-damaged people is without any scientific foundation. Birth defects appear to be no more common amongst the children of thalidomide-affected parents than in the general population. It is important that thalidomide-affected adults are firmly reassured on this point. Most of them have now completed their own families, but they may still worry about their grandchildren. Therefore, unless and until further supportive evidence is reported by a separate and independent source, the answer to the question, 'Can thalidomide cause second generation defects?' is a very definite 'No.'

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9825947     DOI: 10.2165/00002018-199819050-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  9 in total

1.  Recognition of thalidomide defects.

Authors:  R W Smithells; C G Newman
Journal:  J Med Genet       Date:  1992-10       Impact factor: 6.318

2.  Amniotic band sequence in child of thalidomide victim.

Authors:  R Tenconi; M Clementi; L Notari; V R Lo Vasco
Journal:  BMJ       Date:  1994-11-26

Review 3.  Never-ending tales of the mode of the teratogenic action of thalidomide.

Authors:  D Neubert
Journal:  Teratog Carcinog Mutagen       Date:  1997

4.  Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women.

Authors:  A L Herbst; H Ulfelder; D C Poskanzer
Journal:  N Engl J Med       Date:  1971-04-15       Impact factor: 91.245

5.  Is thalidomide mutagenic?

Authors:  J Ashby; H Tinwell
Journal:  Nature       Date:  1995-06-08       Impact factor: 49.962

6.  Thalidomide may be a mutagen.

Authors:  R W Smithells
Journal:  BMJ       Date:  1994-08-13

7.  Thalidomide may be a mutagen.

Authors:  W G McBride
Journal:  BMJ       Date:  1994-06-18

8.  Thalidomide induced alteration in secondary structure of rat embryonic DNA in vivo.

Authors:  P H Huang; W G McBride
Journal:  Teratog Carcinog Mutagen       Date:  1990

9.  Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo.

Authors:  P H Huang; W G McBride
Journal:  Teratog Carcinog Mutagen       Date:  1997
  9 in total
  2 in total

Review 1.  Potential novel uses of thalidomide: focus on palliative care.

Authors:  V Peuckmann; M Fisch; E Bruera
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 2.  Undercover: gene control by metabolites and metabolic enzymes.

Authors:  Jan A van der Knaap; C Peter Verrijzer
Journal:  Genes Dev       Date:  2016-11-01       Impact factor: 11.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.